NCT04895748 2026-03-03DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesNovartisPhase 1 Terminated40 enrolled
NCT04544111 2025-10-07PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting19 enrolled
NCT02404441 2022-08-03Phase I/II Study of PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Completed319 enrolled 41 charts